http://www.biotechdaily.com.au/index.php

Biotech Daily Home

Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy.

Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector.

The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter.

Subscriptions are $A1250 a year (including GST in Australia) and a 10% discount is available for members of AusBiotech, the Bio-Melbourne Network and Life Sciences Queensland.

Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.

 

Download subscription form here
 

 

 

Latest News !
 

2017 - The Year In Review
- CEO, Chairman, Kamikaze of the Year; Capital Raisings

Senator Michaelia Cash Appointed Innovation Minister
- Biotech Daily Editorial Comment

Dr Boreham's Crucible - Admedus

Rhythm Bio $9m IPO For Bowel Cancer Blood Test 

Telix $50m IPO Up 25% For Molecular Targeted Cancer Radiation 

Living Cell Tumbles 89% On NTCell Parkinson's Results

Biotech Daily 12th Birthday Editorial

Biotech Daily Editorial - Selective Briefings 

Biotech Revenue Up 194% In 8 Years To $1.4b

4-Year Data Backs Prota, MCRI Peanut Immunotherapy

WEHI $405m+ Canada Venetoclax For Cancer Deal

10-Year BDI-40 Up 80%, ASX200 Down 9% Big Caps Up 270%

Novartis Buys Spinifex For $916m

 

 

2017: BDI-40 Up 7%, ASX 2% Big Caps 33%

December BDI-40 Up 8%, ASX200 7%: Uscom Up 71%, LBT Down 22%
 

Jan 1, 2017

 
The Biotech Daily Top-40 Index (BDI-40) climbed 6.8 percent in the year to December 31 2017, compared to the S&P ASX200 up 1.6 percent, while the three Big Caps of Cochlear, CSL and Resmed (which are not in the BDI-40) climbed 33.25 percent for the 12 months.
 
Due to unforeseen circumstances, the BDI-40 January 1, 2017 data was not captured and the comparison is with an average of the November 30, 2016 and January 31, 2017 data. The same is the case for the Big Caps, while the ASX and Nasdaq Biotechnology Index (NBI) comparisons are for the 12-month time period (see charts below).
 
For the 12 months to December 31, 2017, the NBI climbed 21.1 percent.
 
In the month to December 31, 2017, the BDI-40 was up 8.0 percent, the ASX200 climbed 7.0 percent, the Big Caps eased 2.0 percent to their second highest market capitalizations and the NBI was up 1.5 percent.
 
Twenty-four of the Biotech Daily Top 40 companies were up, 13 fell and three were unchanged in December. Six companies added more than $50 million each to the index.
  
Sirtex ended its annus horribilius of 2017 as the biggest of the biotechs, at a market capitalization of $921 million, just ahead of Pro Medicus at $901 million, with Nanosonics third at $829 million.
 
December was generally a quiet month for biotechnology companies, with a raft of small rises in the BDI-20 and small falls in the Second 20.
 
Uscom was the best by percentage, up $12 million or 70.6 percent to $29 million, followed by Polynovo (37.1%), Pro Medicus (15.5%), Neuren (15.2%), Viralytics (14.5%), Medical Developments (13.4%), Nanosonics (9.1%) and Sirtex (7.1%).
 
LBT led the falls, down 22.2 percent to $28 million, followed by Dimerix (14.3%), Psivida (13.0%), Universal Biosensors (11.7%) and Immutep (Prima) down 10.2 percent.
 
Outside the BDI-40, a number of companies made significant gains in 2017, with Bioxyne climbing from $4 million to $59 million, Creso Pharma rising from $7 million to $79 million and Noxopharm improving from $20 million to $64 million.
 
On the Nasdaq, Aviragen (formerly Biota) continued its fall to $28 million, while Protagonist hit a record high of $545 million and Redhill slipped $2 million to $140 million.
 
BDI-40 v S&P ASX200 Jun 30, 2006 to Dec 31, 2017 
 
BDI-40 v S&P ASX200 Dec 31, 2016 to Dec 31, 2017 
 
 
Big Caps (Cochlear, CSL, Resmed) Year To Dec 31, 2017
 
 

 

 Click here for Biotech Daily's archive

 

   

Biotech Daily Top 40 With Market Capitalization At Dec 31, 2017

 

* Biotech Daily editor, David Langsam, owns shares in Acrux, Benitec, Mesoblast, Nanosonics, Optiscan, Telix
   and Volpara, as well as non-biotechnology stocks.
   Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies. 

   These holdings are liable to change: http://www.australianethical.com.au/who-we-invest-in